Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Shah MA, Kelsen DP: Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J. Natl Compr. Canc. Netw.8(4),437–447 (2010).Crossref, Medline, CAS, Google Scholar
• 2  Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol.24(14),2137–2150 (2006).Crossref, Medline, Google Scholar
• 3  Cunningham SC, Kamangar F, Kim MP et al.: Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. J. Gastrointest. Surg.9(5),718–725 (2005).Crossref, Medline, Google Scholar
• 4  Cunningham D, Starling N, Rao S et al.: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med.358(1),36–46 (2008).Crossref, Medline, CAS, Google Scholar
• 5  Kang YK, Kang WK, Shin DB et al.: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised Phase III noninferiority trial. Ann. Oncol.20(4),666–673 (2009).Crossref, Medline, Google Scholar
• 6  Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol.24(18),2903–2909 (2006).Crossref, Medline, CAS, Google Scholar
• 7  Van Cutsem E, Moiseyenko VM, Tjulandin S et al.: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol.24(31),4991–4997 (2006).Crossref, Medline, CAS, Google Scholar
• 8  Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science235(4785),177–182 (1987).Crossref, Medline, CAS, Google Scholar
• 9  Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med.353(16),1659–1672 (2005).Crossref, Medline, CAS, Google Scholar
• 10  Romond EH, Perez EA, Bryant J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med.353(16),1673–1684 (2005).Crossref, Medline, CAS, Google Scholar
• 11  Slamon DJ, Leyland-Jones B, Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344(11),783–792 (2001).Crossref, Medline, CAS, Google Scholar
• 12  Smith I, Procter M, Gelber RD et al.: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet369(9555),29–36 (2007).Crossref, Medline, CAS, Google Scholar
• 13  Koeppen HK, Wright BD, Burt AD et al.: Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology38(2),96–104 (2001).Crossref, Medline, CAS, Google Scholar
• 14  Slamon DJ, Godolphin W, Jones LA et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science244(4905),707–712 (1989).Crossref, Medline, CAS, Google Scholar
• 15  Gravalos C, Jimeno A: HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol.19(9),1523–1529 (2008).▪▪ Review of the role of HER2 in gastric cancer.Crossref, Medline, CAS, Google Scholar
• 16  Park DI, Yun JW, Park JH et al.: HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig. Dis. Sci.51(8),1371–1379 (2006).Crossref, Medline, CAS, Google Scholar
• 17  Hofmann M, Stoss O, Shi D et al.: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology52(7),797–805 (2008).▪ Initial guidance on scoring considerations for HER2 testing in gastric cancer.Crossref, Medline, CAS, Google Scholar
• 18  Tanner M, Hollmen M, Junttila TT et al.: Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol.16(2),273–278 (2005).Crossref, Medline, CAS, Google Scholar
• 19  Grabsch H, Sivakumar S, Gray S, Gabbert HE, Muller W: HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value – conclusions from 924 cases of two independent series. Cell. Oncol.32(1–2),57–65 (2010).Medline, Google Scholar
• 20  Chung HC, Bang YJ, Xu JM et al.: Human epidermal growth factor receptor 2 (HER2) in gastric cancer (GC): results of the ToGA trial screening programme and recommendations for HER2 testing. Presented at: European Cancer Organisation 15/European Society for Medical Oncology 34. Berlin, Germany, 20–24 September 2009.Google Scholar
• 21  Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A: Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res.50(5),1550–1558 (1990).Medline, CAS, Google Scholar
• 22  Lewis GD, Figari I, Fendly B et al.: Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother.37(4),255–263 (1993).Crossref, Medline, CAS, Google Scholar
• 23  Carter P, Presta L, Gorman CM et al.: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl Acad. Sci. USA89(10),4285–4289 (1992).Crossref, Medline, CAS, Google Scholar
• 24  Cho HS, Mason K, Ramyar KX et al.: Structure of the extracellular region of HER2 alone and in complex with the herceptin Fab. Nature421(6924),756–760 (2003).Crossref, Medline, CAS, Google Scholar
• 25  Hudis CA: Trastuzumab – mechanism of action and use in clinical practice. N. Engl. J. Med.357(1),39–51 (2007).▪ Overview of trastuzumab activity and clinical potential.Crossref, Medline, CAS, Google Scholar
• 26  Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res.62(14),4132–4141 (2002).Medline, CAS, Google Scholar
• 27  Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J: Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res.61(12),4744–4749 (2001).Medline, CAS, Google Scholar
• 28  Barok M, Isola J, Palyi-Krekk Z et al.: Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol. Cancer Ther.6(7),2065–2072 (2007).Crossref, Medline, CAS, Google Scholar
• 29  Musolino A, Naldi N, Bortesi B et al.: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol.26(11),1789–1796 (2008).Crossref, Medline, CAS, Google Scholar
• 30  Kim SY, Kim HP, Kim YJ et al.: Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int. J. Oncol.32(1),89–95 (2008).Medline, Google Scholar
• 31  Normanno N, Campiglio M, De LA et al.: Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol.13(1),65–72 (2002).Crossref, Medline, CAS, Google Scholar
• 32  Pegram M, Hsu S, Lewis G et al.: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene18(13),2241–2251 (1999).Crossref, Medline, CAS, Google Scholar
• 33  Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ: The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene15(5),537–547 (1997).Crossref, Medline, CAS, Google Scholar
• 34  Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y: Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother. Pharmacol.59(6),795–805 (2007).▪ Preclinical findings indicating potential for chemotherapy plus trastuzumab in gastric cancer.Crossref, Medline, CAS, Google Scholar
• 35  Tokuda Y, Ohnishi Y, Shimamura K et al.: In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Br. J. Cancer73(11),1362–1365 (1996).Crossref, Medline, CAS, Google Scholar
• 36  Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, Kitano S: Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int. J. Oncol.27(3),681–685 (2005).Medline, CAS, Google Scholar
• 37  Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P: Population pharmacokinetics of trastuzumab in patients with HER2⁺ metastatic breast cancer. Cancer Chemother. Pharmacol.56(4),361–369 (2005).Crossref, Medline, CAS, Google Scholar
• 38  Bang YJ, Van Cutsem E, Feyereislova A et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet376(9742),687–697 (2010).▪▪ Key Phase III results from the Trastuzumab for Gastric Cancer (ToGA) study.Crossref, Medline, CAS, Google Scholar
• 39  Cortes-Funes H, Rivera F, Ales I et al. Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification. Presented at: 43rd American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL, USA, 1–5 June 2007.Google Scholar
• 40  Nicholas G, Cripps C, Au H et al.: Early results of a trial of trastuzumab, cisplatin, and docetaxel (TCD) for the treatment of metastatic gastric cancer overexpressing HER-2. Presented at: 31st European Society for Medical Oncology Congress. Istanbul, Turkey, 29 September–3 October 2006.Google Scholar
• 41  Satoh T, Leon J, Lopez RI et al.: Quality of life results from a Phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer. Presented at: 2010 Gastrointestinal Cancers Symposium. Orlando, FL, USA, 22–24 January 2010.Google Scholar
• 42  Chung HC, Bang Y, Van Cutsem E et al.: (Q)-TWIST analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer. Presented at: 2010 American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL, USA, 4–8 June 2010.Google Scholar
• 43  Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol.24(18),2903–2909 (2006).Crossref, Medline, CAS, Google Scholar
• 44  Al Batran SE, Hartmann JT, Probst S et al.: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J. Clin. Oncol.26(9),1435–1442 (2008).Crossref, Medline, CAS, Google Scholar
• 45  Morris PG, Hudis CA: Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be? J. Clin. Oncol.28(21),3407–3410 (2010).Crossref, Medline, CAS, Google Scholar
• 46  Rüschoff J, Nagelmeier I, Baretton G et al.: HER2 testing in gastric cancer. What is different in comparison to breast cancer? Pathologe31(3),208–217 (2010).Crossref, Medline, Google Scholar
• 47  Geyer CE, Forster J, Lindquist D et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med.355(26),2733–2743 (2006).Crossref, Medline, CAS, Google Scholar
• 48  Hecht JR, Bang YJ, Sobrero A et al.: A Phase III study of CapeOx ± lapatinib in FISH-positive HER2 Locally advanced/metastatic upper gastrointestinal adenocarcinoma: interim safety results. Presented at: European Cancer Organisation 15/ European Society for Medical Oncology 34. Berlin, Germany, 20–24 September 2009.Google Scholar
• 49  Satoh T, Bang Y, Wang J et al.: Interim safety analysis from TYTAN: a Phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer. Presented at: 2010 American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL, USA, 4–8 June 2010.Google Scholar
• 50  Gonzales AJ, Hook KE, Althaus IW et al.: Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol. Cancer Ther.7(7),1880–1889 (2008).Crossref, Medline, CAS, Google Scholar
• 51  Sergina NV, Rausch M, Wang D et al.: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature445(7126),437–441 (2007).Crossref, Medline, CAS, Google Scholar
• 52  Baselga J, Swain SM: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer9(7),463–475 (2009).▪▪ Excellent review describing HER signaling and anti-HER therapies.Crossref, Medline, CAS, Google Scholar
• 53  Hsieh AC, Moasser MM: Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br. J. Cancer97(4),453–457 (2007).Crossref, Medline, CAS, Google Scholar
• 54  Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol.2(2),127–137 (2001).Crossref, Medline, CAS, Google Scholar
• 55  Tzahar E, Waterman H, Chen X et al.: A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell Biol.16(10),5276–5287 (1996).Crossref, Medline, CAS, Google Scholar
• 56  Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell5(4),317–328 (2004).Crossref, Medline, CAS, Google Scholar
• 57  Hughes JB, Berger C, Rodland MS, Hasmann M, Stang E, Madshus IH: Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization. Mol. Cancer Ther.8(7),1885–1892 (2009).Crossref, Medline, CAS, Google Scholar
• 58  Agus DB, Akita RW, Fox WD et al.: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell2(2),127–137 (2002).Crossref, Medline, CAS, Google Scholar
• 59  Nahta R, Hung MC, Esteva FJ: The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res.64(7),2343–2346 (2004).Crossref, Medline, CAS, Google Scholar
• 60  Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M: Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res.69(24),9330–9336 (2009).Crossref, Medline, CAS, Google Scholar
• 61  Yamashita Y, Yorozu K, Kurasawa M, Fujimoto-Ouchi K: Pertuzumab in combination with trastuzumab enhanced the anti-tumor activity in HER2-positive human gastric cancers. Presented at: 101st Annual Meeting of the American Association for Cancer Research. Washington, DC, USA, 17–21 April 2010.Google Scholar
• 62  Baselga J, Gelmon KA, Verma S et al.: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol.28(7),1138–1144 (2010).Crossref, Medline, CAS, Google Scholar
• 63  Junttila T, Fields C, Li G et al.: Trastuzumab–maytansine (T–DM1) retains all the mechanisms of action (MOA) of trastuzumab and is extremely effective in combination with docetaxel. Presented at: EORTC-NCI-AACR Symposium on ‘Molecular Targets and Cancer Therapeutics’. Geneva, Switzerland, 21–24 October 2008.Google Scholar
• 64  Lewis Phillips GD, Li G, Dugger DL et al.: Targeting HER2-positive breast cancer with trastuzumab–DM1, an antibody–cytotoxic drug conjugate. Cancer Res.68(22),9280–9290 (2008).Crossref, Medline, CAS, Google Scholar
• 65  Parsons K, Crocker L, Leipold D et al.: Efficacy against HER2-positive trastuzumab-insensitive breast cancer models and enhanced response in trastuzumab-sensitive models. Presented at: American Association for Cancer Research Annual Meeting. Los Angeles, CA, USA, 14–18 April 2007.Google Scholar
• 66  Krop I, LoRusso P, Miller D et al.: A Phase II study of trastuzumab–DM1 (T–DM1), a novel HER2 antibody-drug conjugate, in patients with HER2⁺ metastatic breast cancer who were previously treated with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab. Presented at: 33rd Annual San Antonio Breast Cancer Symposium (SABCS). San Antonio, TX, USA, 10–13 December 2009.Google Scholar
• 67  Krop I, LoRusso P, Miller KD: A Phase II study of trastuzumab–DM1 (T–DM1), a novel HER2 antibody-drug conjugate, in patients with HER2⁺ metastatic breast cancer who were previously treated with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab. Presented at: 35th European Society for Medical Oncology (ESMO) Congress. Milan, Italy, 8–12 October 2010.Google Scholar
• 68  Perez EA, Dirix L, Kocsis J et al.: Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized, multicenter, open-label Phase 2 study. Presented at: 35th European Society for Medical Oncology (ESMO) Congress. Milan, Italy, 8–12 October 2010.Google Scholar
• 69  Rüschoff J, Dietel M, Baretton G et al.: HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch.457(3),299–307 (2010).Crossref, Medline, CAS, Google Scholar
• 101  American Cancer Society: Global Cancer Facts and Figures 2007 www.cancer.org/acs/groups/content/@nho/documents/document/caff2007pwsecuredpdf.pdfGoogle Scholar
• 102  SEER Cancer Statistics Review, 1975–2006, National Cancer Institute. Bethesda, MD, USA http://seer.cancer.gov/csr/1975_2006Google Scholar
• 103  NCCN Clinical Practice Guidelines in Oncology. Gastric Cancer 2010 www.nccn.org/professionals/physician_gls/PDF/gastric.pdfGoogle Scholar
• 104  Herceptin^® (trastuzumab). Summary of Product Characteristics. Roche Registration Ltd www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000278/WC500074922.pdfGoogle Scholar
• 105  Herceptin^® (trastuzumab). Label information www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdfGoogle Scholar
• 106  LOGiC – Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: a Phase III global, blinded study designed to evaluate clinical end points and saftey of chemothearpy plus lapatinib http://clinicaltrials.gov/ct2/show/NCT00680901?term=logic&rank=5Google Scholar
• 107  PF-00299804 monotherapy in patients with HER2-positive advanced gastric cancer http://clinicaltrials.gov/ct2/show/NCT01152853?term=PF+00299804&rank=1Google Scholar